查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1974453

精準腫瘤技術市場分析及預測（至2035年）：依類型、產品類型、服務、技術、應用、最終用戶、組件、部署類型及分期分類

Precision Oncology Technologies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Component, Deployment, Stage
出版日期: | 出版商: Global Insight Services | 英文 305 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

精準腫瘤學技術市場預計將從2024年的1,140億美元成長到2034年的3,021億美元，複合年成長率約為9%。精準腫瘤學技術市場整合了基因組學、蛋白質組學和生物資訊學，涵蓋了針對個別癌症特徵量身定做的先進診斷和治療工具。這些技術能夠透過針對獨特的基因突變，實現個人化治療方案並改善患者預後。分子診斷技術的快速發展和癌症研究投入的不斷增加正在推動市場成長，凸顯了生物標記發現和標靶治療的發展機會。

精準腫瘤技術市場受到全球關稅、地緣政治風險和供應鏈動態變化的顯著影響。為因應貿易摩擦，日本和韓國正在加強國內研發能力，以減少對外國技術的依賴。受地緣政治因素和強力的醫療政策的雙重推動，中國正在加速對本土精準腫瘤解決方案的投資。台灣作為重要的半導體供應商，儘管面臨地緣政治風險，但在精準腫瘤技術市場中仍扮演著至關重要的角色。全球精準腫瘤市場正經歷強勁成長，這主要得益於技術進步和癌症發生率的上升。預計到2035年，隨著區域合作的加強和創新水準的提高，該市場將進一步發展。中東地區的衝突透過能源價格波動間接影響市場，可能對營運成本和供應鏈穩定性造成衝擊。

市場區隔
按類型 診斷試劑、治療試劑、預後試劑、預測性生物標記
產品 基因檢測、伴隨診斷、液態生物檢體、次世代定序、免疫組織化學、螢光原位雜合反應
服務 諮詢、基因組分析、數據解讀和臨床試驗服務
科技 基因定序、聚合酵素鏈鎖反應、微陣列、生物資訊學、奈米技術
適應症 乳癌、肺癌、結腸癌、攝護腺癌、黑色素瘤、白血病
最終用戶 醫院、診斷檢查室、研究機構、製藥和生物技術公司
成分 軟體、硬體、試劑、試劑盒、耗材
實施表格 本機部署、雲端部署、混合式部署
階段 早期癌症、晚期癌症、復發性癌症

精準癌症治療技術市場正迅速發展，這主要得益於個人化癌症治療和基因組分析技術的進步。在診斷領域，基因檢測憑藉其識別特定突變並指導標靶治療的能力，已成為表現最佳的細分市場；其次是液態生物檢體技術，該技術為監測疾病進展和治療反應提供了非侵入性選擇。在治療領域，標靶治療利用分子層面的洞見開發精準攻擊癌細胞的藥物，佔據主導。免疫療法，尤其是查核點抑制劑，是成長速度第二快的細分市場，這反映了其對癌症治療的變革性影響。

人工智慧在精準腫瘤學領域的應用正在不斷推進，提高了診斷準確性，並實現了治療的個人化。人工智慧驅動的數據分析和預測建模平台正成為腫瘤科醫生不可或缺的工具。生物技術公司與研究機構之間的合作正在促進創新，並加速新型治療方法和診斷方法的發展。在改善患者預後和降低成本的潛力驅動下，對精準腫瘤學技術的投資預計將持續成長。

精準腫瘤技術市場的特徵是市場佔有率、定價策略和新產品推出之間存在著動態的相互作用。主要企業正致力於開發創新解決方案，以提高診斷準確性和治療效果。受技術進步和個人化癌症治療需求的推動，價格競爭仍然激烈。頻繁的新產品發布反映了該行業為滿足未被滿足的需求和改善患者預後所做的努力。癌症發生率的上升和對精準醫療日益成長的重視正在推動市場發展。

在競爭格局中，主要參與者不斷相互參照，以保持競爭優勢。監管影響顯著，嚴格的指導方針規範產品開發和核准流程。策略聯盟和合作也影響市場格局，增強了研發能力和市場覆蓋率。北美和歐洲在監管標準方面處於領先地位，而亞太新興市場正迅速採用精準腫瘤學技術。人工智慧和基因組學的融合有望徹底改變市場，帶來巨大的成長前景。

主要趨勢和促進因素：

精準腫瘤學技術市場正經歷強勁成長，這主要得益於幾個關鍵趨勢和促進因素。其中一個關鍵趨勢是基因測序技術的進步，該技術能夠更精確地識別癌症突變，而這對於制定個人化治療方案至關重要。這項技術進步使得精準腫瘤學更加普及且更具成本效益。

另一個趨勢是製藥公司和科技公司之間合作日益增加。這些夥伴關係正在加速創新診斷工具和治療方法的研發和商業化。此外，人工智慧和機器學習在腫瘤學領域的應用正在增強預測分析能力，從而改善患者預後並提高治療效率。

全球癌症發生率的不斷攀升推動了市場的發展，也刺激了對更具針對性和更有效治療方法的需求。各國政府和醫療機構正大力投資精準醫療舉措，並認知到其在革新癌症治療方面的潛力。以患者為中心的醫療模式的興起也促進了精準腫瘤學的應用，因為患者和醫療服務提供者都在尋求能夠提高生活品質和存活率的個人化治療方案。這些趨勢和促進因素有望推動精準腫瘤學技術市場實現顯著成長，並為相關人員帶來盈利的機會。

限制與挑戰：

精準腫瘤學技術市場面臨許多重大限制與挑戰。首先，精準腫瘤學治療和技術的高成本限制了其可近性，尤其是在低收入地區。這一經濟障礙阻礙了技術的廣泛應用，也限制了患者獲得最先進治療的機會。其次，癌症基因組學的複雜性和多樣性為數據解讀和臨床決策帶來了挑戰。這種複雜性需要高度專業的知識，而這些知識並非總是唾手可得。第三，監管障礙和冗長的核准流程會延緩新技術進入市場和創新。這些監管方面的挑戰有可能阻礙技術進步的步伐。第四，精準腫瘤學缺乏標準化通訊協定導致治療結果不一致。這種缺乏標準化的現狀使得精準腫瘤學難以融入常規臨床實踐。最後，由於精準腫瘤學涉及敏感的患者訊息，因此強力的數據隱私和安​​全措施至關重要。確保遵守資料保護條例仍然是一項重大挑戰。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章：細分市場分析

  • 市場規模及預測：依類型
    • 診斷試劑
    • 治療藥物
    • 預後
    • 預測性生物標記
  • 市場規模及預測：依產品分類
    • 基因檢測
    • 伴隨診斷
    • 液態生物檢體
    • 次世代定序
    • 免疫組織化學
    • 螢光原位雜合反應
  • 市場規模及預測：依服務分類
    • 諮詢
    • 基因組分析
    • 數據解讀
    • 臨床試驗服務
  • 市場規模及預測：依技術分類
    • 基因定序
    • 聚合酵素鏈鎖反應
    • 微陣列
    • 生物資訊學
    • 奈米科技
  • 市場規模及預測：依應用領域分類
    • 乳癌
    • 肺癌
    • 大腸直腸癌
    • 攝護腺癌
    • 黑色素瘤
    • 白血病
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診斷檢查室
    • 研究所
    • 製藥公司
    • 生技公司
  • 市場規模及預測：依組件分類
    • 軟體
    • 硬體
    • 試劑
    • 成套工具
    • 消耗品
  • 市場規模及預測：依發展狀況
    • 本地部署
    • 基於雲端的
    • 混合
  • 市場規模及預測：依疾病階段分類
    • 早期癌症
    • 晚期癌症
    • 復發性癌症

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 監管概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章：公司簡介

  • Guardant Health
  • Foundation Medicine
  • Caris Life Sciences
  • Tempus
  • Natera
  • Neo Genomics
  • Personalis
  • Adaptive Biotechnologies
  • Biodesix
  • Invitae
  • Onco Cyte
  • Freenome
  • Grail
  • Helix
  • Bristol Myers Squibb
  • Illumina
  • Strata Oncology
  • Genomic Health
  • Oncocyte Corporation
  • Epic Sciences

第9章 關於我們

簡介目錄
Product Code: GIS32792

Precision Oncology Technologies Market is anticipated to expand from $114.0 Billion in 2024 to $302.1 Billion by 2034, growing at a CAGR of approximately 9%. The Precision Oncology Technologies Market encompasses advanced diagnostic and therapeutic tools tailored to individual cancer profiles, integrating genomics, proteomics, and bioinformatics. These technologies enable personalized treatment plans, improving patient outcomes by targeting unique genetic mutations. Rapid advancements in molecular diagnostics and increased investment in cancer research are propelling market growth, highlighting opportunities in biomarker discovery and targeted therapies.

The Precision Oncology Technologies Market is significantly influenced by global tariffs, geopolitical risks, and evolving supply chain dynamics. Japan and South Korea are bolstering their domestic capabilities in response to trade tensions, aiming to reduce dependency on foreign technologies. China is accelerating its investment in homegrown precision oncology solutions, driven by both geopolitical factors and a robust healthcare agenda. Taiwan, pivotal in semiconductor supply, faces geopolitical vulnerabilities yet remains indispensable. The global market for precision oncology is witnessing robust growth, driven by technological advancements and rising cancer prevalence. By 2035, the market is expected to evolve with increased regional collaborations and innovation. Middle East conflicts may indirectly affect the market through energy price volatility, influencing operational costs and supply chain stability.

Market Segmentation
TypeDiagnostics, Therapeutics, Prognostics, Predictive Biomarkers
ProductGenetic Tests, Companion Diagnostics, Liquid Biopsy, Next-Generation Sequencing, Immunohistochemistry, Fluorescence In Situ Hybridization
ServicesConsultation, Genomic Profiling, Data Interpretation, Clinical Trial Services
TechnologyGene Sequencing, Polymerase Chain Reaction, Microarray, Bioinformatics, Nanotechnology
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia
End UserHospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies, Biotechnology Firms
ComponentSoftware, Hardware, Reagents, Kits, Consumables
DeploymentOn-Premises, Cloud-Based, Hybrid
StageEarly-Stage Cancer, Advanced-Stage Cancer, Recurrent Cancer

The Precision Oncology Technologies Market is evolving rapidly, propelled by advancements in personalized cancer treatment and genomic profiling. Within the diagnostics segment, genetic testing emerges as the top-performing sub-segment, driven by its ability to identify specific mutations and guide targeted therapies. Liquid biopsy technologies follow closely, offering non-invasive options for monitoring disease progression and treatment response. In the therapeutics segment, targeted therapy leads, leveraging molecular insights to develop drugs that precisely attack cancer cells. Immunotherapy, particularly checkpoint inhibitors, represents the second highest-performing sub-segment, reflecting its transformative impact on cancer care.

The integration of artificial intelligence in precision oncology is gaining momentum, enhancing diagnostic accuracy and treatment personalization. AI-driven platforms for data analysis and predictive modeling are becoming indispensable tools for oncologists. Collaboration between biotech firms and research institutions is fostering innovation, accelerating the development of novel therapeutics and diagnostic approaches. Investment in precision oncology technologies is expected to continue, driven by the promise of improved patient outcomes and reduced healthcare costs.

The Precision Oncology Technologies Market is characterized by a dynamic interplay of market share, pricing strategies, and new product introductions. Leading companies are focusing on innovative solutions that enhance diagnostic accuracy and treatment efficacy. Pricing remains competitive, influenced by technological advancements and the demand for personalized cancer therapies. New product launches are frequent, reflecting the sector's commitment to addressing unmet medical needs and improving patient outcomes. The market is buoyed by the increasing prevalence of cancer and the growing emphasis on precision medicine.

In terms of competition, key players are continuously benchmarking against each other to maintain a competitive edge. Regulatory influences are significant, with stringent guidelines shaping product development and approval processes. The market landscape is further influenced by strategic alliances and collaborations, enhancing research capabilities and market reach. North America and Europe are at the forefront of regulatory standards, while emerging markets in Asia-Pacific are rapidly adopting precision oncology technologies. The integration of artificial intelligence and genomics is poised to revolutionize the market, offering substantial growth prospects.

Geographical Overview:

The Precision Oncology Technologies Market is witnessing a dynamic expansion across various regions, each contributing uniquely to its growth. North America leads, driven by advanced healthcare infrastructure and substantial investments in precision medicine research. The presence of major biotech firms accelerates technological advancements, enhancing the region's market dominance. In Europe, robust government initiatives supporting personalized medicine and a strong focus on research and development are propelling market growth.

The region's emphasis on regulatory frameworks also fosters a conducive environment for innovation. In the Asia Pacific, the market is burgeoning, fueled by increasing cancer prevalence and rising healthcare expenditures. Countries like China and India are emerging as significant players, driven by technological advancements and growing awareness of precision oncology. Latin America and the Middle East & Africa are gradually recognizing the potential of precision oncology technologies. These regions are witnessing increased investments and collaborations, paving the way for future growth and innovation.

Recent Developments:

The Precision Oncology Technologies Market has experienced notable developments in recent months. Roche announced a strategic partnership with Illumina to enhance its precision oncology offerings, focusing on integrating genomic sequencing technologies to optimize cancer treatment strategies. This collaboration aims to accelerate the development of personalized cancer therapies.

In another significant move, Thermo Fisher Scientific completed the acquisition of a leading genomic diagnostics company, augmenting its capabilities in precision oncology. This acquisition is expected to bolster Thermo Fisher's portfolio, enabling more comprehensive diagnostic solutions for oncology patients.

Meanwhile, Guardant Health launched an innovative liquid biopsy test designed to provide real-time insights into tumor genetics, offering a less invasive alternative to traditional biopsies. This product launch is anticipated to revolutionize cancer diagnostics by enhancing the precision of treatment decisions.

On the regulatory front, the U.S. FDA has introduced new guidelines to expedite the approval process for precision oncology drugs, aiming to bring innovative treatments to market more swiftly. This regulatory shift is likely to stimulate further advancements in the sector.

Financially, the precision oncology market has attracted substantial investment, with venture capital firms injecting significant funds into startups specializing in AI-driven oncology solutions. This influx of capital underscores the market's potential and the growing interest in leveraging technology to transform cancer care.

Key Trends and Drivers:

The Precision Oncology Technologies Market is experiencing robust expansion, fueled by several key trends and drivers. A significant trend is the advancement of genomic sequencing technologies, enabling more precise identification of cancer mutations, which is crucial for personalized treatment plans. This technological progress is making precision oncology more accessible and cost-effective.

Another trend is the growing collaboration between pharmaceutical companies and technology firms. These partnerships are accelerating the development and commercialization of innovative diagnostic tools and treatments. Furthermore, the integration of artificial intelligence and machine learning in oncology is enhancing predictive analytics, leading to improved patient outcomes and treatment efficiency.

Drivers of this market include the increasing prevalence of cancer worldwide, prompting a demand for more targeted and effective therapies. Governments and healthcare institutions are investing heavily in precision medicine initiatives, recognizing their potential to revolutionize cancer treatment. The rise of patient-centric care models is also driving the adoption of precision oncology, as patients and healthcare providers seek tailored treatment options that improve quality of life and survival rates. With these trends and drivers, the Precision Oncology Technologies Market is poised for substantial growth, offering lucrative opportunities for stakeholders.

Restraints and Challenges:

The Precision Oncology Technologies Market is confronted with several significant restraints and challenges. Firstly, the high cost of precision oncology treatments and technologies restricts their accessibility, particularly in low-income regions. This financial barrier hinders widespread adoption and limits patient access to cutting-edge therapies. Secondly, the complexity and variability of cancer genomics present challenges in data interpretation and clinical decision-making. This complexity demands highly specialized expertise, which is not always readily available. Thirdly, regulatory hurdles and lengthy approval processes for new technologies can delay market entry and innovation. These regulatory challenges can stifle the pace of technological advancement. Fourthly, there is a lack of standardized protocols for precision oncology, leading to inconsistencies in treatment outcomes. This absence of standardization complicates the integration of precision oncology into routine clinical practice. Lastly, the need for robust data privacy and security measures is critical, as sensitive patient information is integral to precision oncology. Ensuring compliance with data protection regulations remains a formidable challenge.

Key Companies:

Guardant Health, Foundation Medicine, Caris Life Sciences, Tempus, Natera, Neo Genomics, Personalis, Adaptive Biotechnologies, Biodesix, Invitae, Onco Cyte, Freenome, Grail, Helix, Bristol Myers Squibb, Illumina, Strata Oncology, Genomic Health, Oncocyte Corporation, Epic Sciences

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Component
  • 2.8 Key Market Highlights by Deployment
  • 2.9 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Diagnostics
    • 4.1.2 Therapeutics
    • 4.1.3 Prognostics
    • 4.1.4 Predictive Biomarkers
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Genetic Tests
    • 4.2.2 Companion Diagnostics
    • 4.2.3 Liquid Biopsy
    • 4.2.4 Next-Generation Sequencing
    • 4.2.5 Immunohistochemistry
    • 4.2.6 Fluorescence In Situ Hybridization
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Consultation
    • 4.3.2 Genomic Profiling
    • 4.3.3 Data Interpretation
    • 4.3.4 Clinical Trial Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Gene Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Microarray
    • 4.4.4 Bioinformatics
    • 4.4.5 Nanotechnology
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
    • 4.5.5 Melanoma
    • 4.5.6 Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Diagnostic Laboratories
    • 4.6.3 Research Institutes
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Biotechnology Firms
  • 4.7 Market Size & Forecast by Component (2020-2035)
    • 4.7.1 Software
    • 4.7.2 Hardware
    • 4.7.3 Reagents
    • 4.7.4 Kits
    • 4.7.5 Consumables
  • 4.8 Market Size & Forecast by Deployment (2020-2035)
    • 4.8.1 On-Premises
    • 4.8.2 Cloud-Based
    • 4.8.3 Hybrid
  • 4.9 Market Size & Forecast by Stage (2020-2035)
    • 4.9.1 Early-Stage Cancer
    • 4.9.2 Advanced-Stage Cancer
    • 4.9.3 Recurrent Cancer

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Component
      • 5.2.1.8 Deployment
      • 5.2.1.9 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Component
      • 5.2.2.8 Deployment
      • 5.2.2.9 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Component
      • 5.2.3.8 Deployment
      • 5.2.3.9 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Component
      • 5.3.1.8 Deployment
      • 5.3.1.9 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Component
      • 5.3.2.8 Deployment
      • 5.3.2.9 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Component
      • 5.3.3.8 Deployment
      • 5.3.3.9 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Component
      • 5.4.1.8 Deployment
      • 5.4.1.9 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Component
      • 5.4.2.8 Deployment
      • 5.4.2.9 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Component
      • 5.4.3.8 Deployment
      • 5.4.3.9 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Component
      • 5.4.4.8 Deployment
      • 5.4.4.9 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Component
      • 5.4.5.8 Deployment
      • 5.4.5.9 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Component
      • 5.4.6.8 Deployment
      • 5.4.6.9 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Component
      • 5.4.7.8 Deployment
      • 5.4.7.9 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Component
      • 5.5.1.8 Deployment
      • 5.5.1.9 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Component
      • 5.5.2.8 Deployment
      • 5.5.2.9 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Component
      • 5.5.3.8 Deployment
      • 5.5.3.9 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Component
      • 5.5.4.8 Deployment
      • 5.5.4.9 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Component
      • 5.5.5.8 Deployment
      • 5.5.5.9 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Component
      • 5.5.6.8 Deployment
      • 5.5.6.9 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Component
      • 5.6.1.8 Deployment
      • 5.6.1.9 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Component
      • 5.6.2.8 Deployment
      • 5.6.2.9 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Component
      • 5.6.3.8 Deployment
      • 5.6.3.9 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Component
      • 5.6.4.8 Deployment
      • 5.6.4.9 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Component
      • 5.6.5.8 Deployment
      • 5.6.5.9 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Guardant Health
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Foundation Medicine
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Caris Life Sciences
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Tempus
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Natera
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Neo Genomics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Personalis
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Adaptive Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Biodesix
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Invitae
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Onco Cyte
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Freenome
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Grail
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Helix
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Bristol Myers Squibb
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Illumina
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Strata Oncology
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Genomic Health
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Oncocyte Corporation
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Epic Sciences
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us